Infliximab: a new treatment for rheumatoid arthritis.
Infliximab, a chimeric mouse human monoclonal antibody, is an anti-TNF treatment for rheumatoid arthritis. In the past there was a sizeable group of people who had exhausted disease-modifying antirheumatic drugs (DMARDs) and were left largely untreated. This has been revolutionized by treatments such as infliximab which have been shown to be effective for patients in whom standard DMARDs have failed.
Emery
P
P
University of Leeds, Leeds Teaching Hospital Trust, Leeds.
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D003362:Cost-Benefit Analysis; D006801:Humans; D000069285:Infliximab; D018579:Patient Selection; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab